Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Organisation › Details

OSE Immunotherapeutics S.A.

OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi® that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. OSE Pharma’s lead product, Tedopi®, combines 10 “neo-epitopes” directed against five tumour associated antigens. In its most advanced application it is about to enter a pivotal Phase III study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed first line therapy. Tedopi® has orphan drug status in the USA and is considered as personalised medicine in Europe in HLA-A2 positive patients. OSE Pharma is also planning a new Phase II clinical trial in combination with another immunotherapy treatment in NSCLC. Tedopi® targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains a total of ten optimised epitopes, or “neo- epitopes”, designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape. (ISIN : FR0012127173 ; Mnémo : OSE). *


Period Start 2014-09-21 existent
Period End 2016-05-31 merged
  Group OSE Immunotherapeutics (Group)
  Today OSE Pharma S.A.
  Predecessor Effimune SAS
Products Industry Memopi® multi-epitope technology
  Industry 2 Tedopi® cancer immunotherapy
Persons Person Poirier, Nicolas (OSE Immunotherapeutics 202210– CEO + CSO before CSO before Effimune + Tcl Pharma)
  Person 2 Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)
Region Region Nantes
  Country France
  Street 22 boulevard Benoni Goullin
  City 44200 Nantes
  Tel +33-2-2829-1010
    Address record changed: 2024-01-05
Basic data Employees n. a.
  Currency EUR
  Profit -5,584,000 (2015-12-31)
  Cash 15,131,000 (2015-12-31)
    * Document for »About Section«: 
Record changed: 2024-05-22


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for OSE Immunotherapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top